ArticleEuropean heart journal open2026
Narrowing sex differences in pharmacotherapy following invasive angiography for coronary artery disease between 2017 and 2024.
Article in European heart journal open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Women who experience myocardial infarction (MI) and undergo invasive angiography, experience higher morbidity and mortality compared to age-matched male counterparts. The prognostic benefit of optimal medical therapy (OMT) following MI is well established; however, treatment bias has been evidenced historically between the sexes. We explored sex differences in prescribing trends of OMT following invasive angiography for obstructive CAD at a high throughput regional cardiac centre. Methods: We determined discharge medication received by females and males undergoing invasive angiography in 2017, 2019, 2022, and 2024 with obstructive CAD (angiographic lesion ≥50% luminal diameter). Logistic regression was used to determine differences in the main cohort and in subgroups by clinical diagnosis (ACS, STEMI, NSTEMI, stable angina) and age (<55 or ≥55 years). This latter age cut-off to explore pre- and post-menopause trends, respectively. Results: 10 591 patient attendances (22.3% female, Conclusion: These findings demonstrate welcome improvements in equitable prescribing practices for OMT post angiography and highlight the importance of reviewing prescribing practices to ensure evidencing of success in implementing best practice guidelines.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.